Lu-PSMA-617 granted Breakthrough Therapy Designation for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

The designation for this investigational radioligand therapy was based on positive data from the Phase III VISION study, which showed its addition to best standard of care was associated with improved overall survival in patients with progressive PSMA-positive mCRPC.

Source:

Biospace Inc.